Welcome to the Monthly QPS Pharmacology Newsletter

Discover QPS pharmacology services, explore the ultimate guide to oligonucleotides, and catch up on the latest research, breakthroughs and insights on the QPS blog.

Greetings!

QPS Preclinical Pharmacology

The QPS AAALAC-accredited facility offers established subject matter experts and over 20 years of experience conducting preclinical studies that meet or exceed regulatory agency requirements.

Our pharmacology services include in vivo research, biochemical, and histological analyses. Our primary investigators are ready to adapt existing models, or create new models, to meet your specific drug development research needs.

You can rest assured that the QPS Pharmacology team collaborates closely with our DMPK and Toxicology teams to design custom research solutions for your small molecules or biologics.

Contact QPS Today

Download the White Paper

Confidently Choose A CRO to Support Your IND Efforts

Explore QPS Expertise in Oligonucleotides

QPS specializes in oligonucleotide drug development, offering comprehensive services from design and synthesis to testing and analysis.

With over 20 years of experience, QPS supports gene therapy research with precise quantitation methods and extensive expertise in PK, immunogenicity, biodistribution, and ADME studies.

Download the QPS White Paper

Therapeutic Oligonucleotide Metabolite Identification, Profiling and Quantitation

Contact QPS for Your Next Drug Development Study

Discover the Future of Science on the QPS Blog

A Shot at Ending HIV: The Promise of Lenacapavir

HIV remains a global health crisis, infecting more than 1 million people annually. Although research has advanced to treat people who become infected, a vaccine to protect people from infection remains elusive. However, a new injectable drug from Gilead Sciences, lenacapavir, is reshaping the fight against the virus. Unlike pre-exposure prophylaxis (PrEP) pills, which must be taken daily, a single shot of lenacapavir protects against HIV for six months.

Hope for the Future

Vaccine Research at QPS

Squid-Inspired Microjet Device Could Enable More Direct Drug Delivery

A new type of drug delivery device in development could someday bypass the challenges and fears associated with certain types of injectable drugs. In collaboration with Novo Nordisk, researchers at the Massachusetts Institute of Technology (MIT) have designed a groundbreaking needle-free microjet drug delivery system.

A Novel, Creative Design

The Ultimate Guide to Gene Therapy

Click Here to Subscribe to the QPS Blog

Will you be at any of the following conferences?

QPS would love to meet with you.

World ADC - Booth# 18

London, UK

March 3-6, 2025

WRIB - Booth# 47

New Orleans, LA

April 7-11, 2025

AAPS NBC - Booth# 212

New Orleans, LA

May 4-7, 2025

TIDES (Peptides and Oligonucleotides)

San Diego, CA

May 19-22, 2025

Schedule a Meeting with QPS

Visit our website www.qps.com

or contact us at info@qps.com

for an appointment.

www.qps.com | info@qps.com | +1 512 350 2827

We use your email address exclusively for sending QPS newsletters with a special e-mail program. If you no longer wish to receive any mailings, simply use the "unsubscribe" link at the bottom. If you don't unsubscribe, we assume that this consent also applies to the system of the GDPR. (Data protection notice: According to Art. 7 GDPR, the consent can of course also be withdrawn at any time after May 25, 2018.)